Health ❯ Healthcare ❯ Cancer Treatment
Antibody Drug Conjugates EGFR Inhibitors NSD2 Inhibition HER2 Mutations Bispecific Antibodies Zongertinib Research Innovations KRAS G12C Inhibitors RSPO2 Inhibition Small Molecule Therapy Encorafenib and Cetuximab Epigenetic Therapy Antibody-Drug Conjugates HER2-targeting Drugs Triple-Negative Breast Cancer HER2-Directed Therapy FLT3-ITD Mutation CAR-T Cell Therapy Belantamab Mafodotin CDK12 Inhibitors Bruton’s Tyrosine Kinase Inhibitors Encorafenib and Binimetinib NY-ESO-1 Antigen Nectin-4 Therapies BTK Inhibitors EGFR Inhibition Tyrosine Kinase Inhibitors Tumor Suppressors EGFR Tyrosine Kinase Inhibitors Dual Targeting Osimertinib Integrin Beta-6 (IB6) Inhibition Dual Gene Targeting EGFR-Mutated NSCLC Cabozantinib Glycan-Dependent Therapies Extracellular Matrix EGFR-Tyrosine Kinase Inhibitors Aumolertinib NRF2 Inhibitors Datopotamab Deruxtecan Protein Inhibition Viral Mimics Fibroblast Activation Protein siRNA Therapy CAR T Cell Therapy PARP Inhibitors KRAS Mutations PI3Kα Inhibitors Protein Therapy HER2+ Therapy Her2 Positive Breast Cancer Menin Inhibitors Alectinib vs Crizotinib PIK3CA Mutations Trastuzumab Deruxtecan (T-DXd) MEK Inhibitors CD33-Targeted Therapies T-DXd (Enhertu) Drug Approval DLL3-Targeting Antibodies HER2-positive GEA HER2-Positive Therapy CD123-Targeting Therapies Cold Tumors Combination Therapy Immune Checkpoint Inhibitors Chimeric Antigen Receptor Therapy Natural Killer Cells Engineered Bacteria XPO1 Protein
A peer-reviewed Science study reports mouse tumor clearance using ultra-sensitive receptors that detect very low CD70 levels, prompting plans for a first-in-human safety trial.
